178 related articles for article (PubMed ID: 21774759)
1. Xanthine derivatives in the heart: blessed or cursed?
Szentmiklósi AJ; Cseppentō A; Gesztelyi R; Zsuga J; Körtvély A; Harmati G; Nánási PP
Curr Med Chem; 2011; 18(24):3695-706. PubMed ID: 21774759
[TBL] [Abstract][Full Text] [Related]
2. Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties.
Drabczyńska A; Schumacher B; Müller CE; Karolak-Wojciechowska J; Michalak B; Pekala E; Kieć-Kononowicz K
Eur J Med Chem; 2003 Apr; 38(4):397-402. PubMed ID: 12750027
[TBL] [Abstract][Full Text] [Related]
3. Epileptogenic actions of xanthines in relation to their affinities for adenosine A1 receptors in CA3 neurons of hippocampal slices (guinea pig).
Moraidis I; Bingmann D
Brain Res; 1994 Mar; 640(1-2):140-5. PubMed ID: 8004443
[TBL] [Abstract][Full Text] [Related]
4. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
Hayallah AM; Sandoval-Ramírez J; Reith U; Schobert U; Preiss B; Schumacher B; Daly JW; Müller CE
J Med Chem; 2002 Mar; 45(7):1500-10. PubMed ID: 11906291
[TBL] [Abstract][Full Text] [Related]
5. Medicinal chemistry of A2A adenosine receptor antagonists.
Cacciari B; Pastorin G; Spalluto G
Curr Top Med Chem; 2003; 3(4):403-11. PubMed ID: 12570758
[TBL] [Abstract][Full Text] [Related]
6. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Chen JF; Chern Y
Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
[TBL] [Abstract][Full Text] [Related]
7. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.
Yan L; Müller CE
J Med Chem; 2004 Feb; 47(4):1031-43. PubMed ID: 14761205
[TBL] [Abstract][Full Text] [Related]
8. Molecular simulation of 8-styrylxanthines.
Mager PP; Reinhardt R; Richter M; Walther H; Rockel B
Drug Des Discov; 1995 Nov; 13(2):89-107. PubMed ID: 8872454
[TBL] [Abstract][Full Text] [Related]
9. Adenosine A1 receptor down-regulation in mothers and fetal brain after caffeine and theophylline treatments to pregnant rats.
León D; Albasanz JL; Ruíz MA; Fernández M; Martín M
J Neurochem; 2002 Aug; 82(3):625-34. PubMed ID: 12153486
[TBL] [Abstract][Full Text] [Related]
10. Xanthines as adenosine receptor antagonists.
Müller CE; Jacobson KA
Handb Exp Pharmacol; 2011; (200):151-99. PubMed ID: 20859796
[TBL] [Abstract][Full Text] [Related]
11. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
[TBL] [Abstract][Full Text] [Related]
12. [Receptor mediated effects of adenosine and caffeine].
Eikvar L; Kirkebøen KA
Tidsskr Nor Laegeforen; 1998 Mar; 118(9):1390-5. PubMed ID: 9599504
[TBL] [Abstract][Full Text] [Related]
13. Introduction to adenosine receptors as therapeutic targets.
Jacobson KA
Handb Exp Pharmacol; 2009; (193):1-24. PubMed ID: 19639277
[TBL] [Abstract][Full Text] [Related]
14. Structures of Human A
Cheng RKY; Segala E; Robertson N; Deflorian F; Doré AS; Errey JC; Fiez-Vandal C; Marshall FH; Cooke RM
Structure; 2017 Aug; 25(8):1275-1285.e4. PubMed ID: 28712806
[TBL] [Abstract][Full Text] [Related]
15. Novel trends in the treatment of cardiovascular disorders: site- and event- selective adenosinergic drugs.
Szentmiklósi AJ; Cseppento A; Harmati G; Nánási PP
Curr Med Chem; 2011; 18(8):1164-87. PubMed ID: 21291368
[TBL] [Abstract][Full Text] [Related]
16. 8-Azaxanthine derivatives as antagonists of adenosine receptors.
Franchetti P; Messini L; Cappellacci L; Grifantini M; Lucacchini A; Martini C; Senatore G
J Med Chem; 1994 Sep; 37(18):2970-5. PubMed ID: 8071944
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2).
Feoktistov I; Garland EM; Goldstein AE; Zeng D; Belardinelli L; Wells JN; Biaggioni I
Biochem Pharmacol; 2001 Nov; 62(9):1163-73. PubMed ID: 11705449
[TBL] [Abstract][Full Text] [Related]
18. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists.
El Yacoubi M; Ledent C; Parmentier M; Costentin J; Vaugeois JM
Psychopharmacology (Berl); 2000 Feb; 148(2):153-63. PubMed ID: 10663430
[TBL] [Abstract][Full Text] [Related]
19. Health benefits of methylxanthines in cacao and chocolate.
Franco R; Oñatibia-Astibia A; Martínez-Pinilla E
Nutrients; 2013 Oct; 5(10):4159-73. PubMed ID: 24145871
[TBL] [Abstract][Full Text] [Related]
20. Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors.
Imaizumi M; Miyazaki S; Onodera K
Methods Find Exp Clin Pharmacol; 1994 Nov; 16(9):639-44. PubMed ID: 7746025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
